HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BioNTech (NASDAQ:BNTX) and maintained a price target of $113.
May 28, 2024 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BioNTech and maintained a price target of $113, indicating continued confidence in the company's stock performance.
The reiteration of a Buy rating and the maintenance of a $113 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and support the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100